Literature DB >> 3709528

Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia.

M Brufani, M Marta, M Pomponi.   

Abstract

The anticholinesterase activity of a new carbamate, heptylphysostigmine, was studied in vitro. This compound is a competitive inhibitor of acetylcholinesterase (or true cholinesterase) having Ki = (1 +/- 0.5) X 10(-7) M. The inhibition was instantaneous at the onset and did not diminish with prolonged incubation of the drug and enzyme.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709528     DOI: 10.1111/j.1432-1033.1986.tb09646.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  11 in total

1.  Studies on new, centrally active and reversible acetylcholinesterase inhibitors.

Authors:  F Arnal; L J Coté; S Ginsburg; G D Lawrence; A Naini; M Sano
Journal:  Neurochem Res       Date:  1990-06       Impact factor: 3.996

2.  Kinetics of cholinesterase inhibition by eptastigmine in man.

Authors:  L K Unni; V Hutt; B P Imbimbo; R E Becker
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 4.  Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

Authors:  B P Imbimbo
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 5.  Cognitive enhancement therapy for Alzheimer's disease. The way forward.

Authors:  L Parnetti; U Senin; P Mecocci
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

6.  The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.

Authors:  P De Sarno; M Pomponi; E Giacobini; X C Tang; E Williams
Journal:  Neurochem Res       Date:  1989-10       Impact factor: 3.996

7.  Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects.

Authors:  A Auteri; A Mosca; N Lattuada; M Luzzana; L Zecca; D Radice; B P Imbimbo
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Preferential inhibition of acetylcholinesterase molecular forms in rat brain.

Authors:  N Ogane; E Giacobini; E Messamore
Journal:  Neurochem Res       Date:  1992-05       Impact factor: 3.996

Review 9.  Diagnostic and pharmacological approaches in Alzheimer's disease.

Authors:  C Hermann; R G Stern; M F Losonzcy; S Jaff; M Davidson
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

Review 10.  Clinical pharmacokinetics of drugs for Alzheimer's disease.

Authors:  L Parnetti
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.